{"nctId":"NCT04078126","briefTitle":"Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.","startDateStruct":{"date":"2019-09-10","type":"ACTUAL"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":35,"armGroups":[{"label":"Budesonide and formoterol fumarate (MDI BFF)","type":"EXPERIMENTAL","interventionNames":["Combination Product: BFF"]},{"label":"Symbicort Turbuhaler","type":"ACTIVE_COMPARATOR","interventionNames":["Combination Product: Symbicort Turbuhaler"]}],"interventions":[{"name":"BFF","otherNames":[]},{"name":"Symbicort Turbuhaler","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Subject must be 40 to 80 years of age inclusive, at the time of signing the ICF.\n2. Individuals who have a physician diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)\n3. Require COPD maintenance therapy: all subjects must be receiving 2 or more inhaled maintenance therapies, including at least 1 long-acting bronchodilator, for the management of their COPD for at least 4 weeks prior to Visit 1.\n4. A post-bronchodilator FEV1/FVC of \\<0.70 and post-bronchodilator FEV1 of \\<50% predicted normal value at Visit 2.\n5. A pre-bronchodilator PIF of \\<50 L/min using the InCheck Inspiratory Flow Measurement Device set to Turbuhaler S resistance at Visit 2.\n6. Current or former smokers with history of at least 10 pack-years of cigarette smoking.\n\nKey Exclusion Criteria:\n\n1. Current diagnosis of asthma, in the opinion of the Investigator.\n2. Other respiratory disorders including known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis (high resolution CT evidence of bronchiectasis that causes repeated acute exacerbations), immune deficiency disorders, severe neurological disorders affecting control of the upper airway, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or pulmonary thromboembolic disease.\n3. A moderate or severe exacerbation of COPD ending within 6 weeks prior to randomization (Visit 3).\n4. Need for mechanical ventilation within 3 months prior to Visit 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Peak Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Within 4 Hours Post-dose Following 1 Week of Treatment","description":"Peak change from baseline in FEV1 within 4 hours post-dose was defined as the maximum of the FEV1 assessments within 4 hours post-dosing at each visit minus baseline, provided that there were at least 2 non-missing values during the first 4 hours post dose.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.256","spread":null},{"groupId":"OG001","value":"0.274","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve for Change From Baseline in FEV1 From Area Under the Curve 0 to 4 Hours (AUC0-4 h) Following 1 Week of Treatment","description":"FEV1 AUC0-4 was calculated using the trapezoidal rule and was normalized by dividing by the time in hours from dosing to the last measurement included (typically 4 hours).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.194","spread":null},{"groupId":"OG001","value":"0.210","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pre-dose FEV1 Following 1 Week of Treatment","description":"Change from baseline in pre-dose FEV1 following 1 week of treatment was defined as the 45-minute pre-dose value following 1 week of treatment minus baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.081","spread":null},{"groupId":"OG001","value":"0.087","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post-dose Inspiratory Capacity (IC) Following 1 Week of Treatment","description":"Change from baseline in 2-hour post-dose IC following 1 week of treatment was defined as the 2-hour post-dose assessment of IC following 1 week of treatment minus baseline IC.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.379","spread":null},{"groupId":"OG001","value":"0.411","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pre-dose Peak Inspiratory Flow (PIF; InCheck Device Set to no Resistance) Following 1 Week of Treatment","description":"Change from baseline in pre-dose PIF (InCheck device set to no resistance) following 1 week of treatment was defined as the pre-dose PIF (InCheck device set to no resistance) following 1 week of treatment minus baseline PIF. (The InCheck Inspiratory Flow Measurement Device is an inhalation airflow meter that may be set to various resistances similar to marketed inhaler products. For this measurement, the device was set to no resistance.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":null},{"groupId":"OG001","value":"5.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pre-dose PIF (Resistance Set Equal to Turbuhaler S) Following 1 Week of Treatment","description":"Change from baseline in pre-dose PIF (resistance set equal to Turbuhaler S) following 1 week of treatment was defined as the pre-dose PIF (resistance set equal to Turbuhaler S) following 1 week of treatment minus baseline PIF. (The InCheck Inspiratory Flow Measurement Device is an inhalation airflow meter that may be set to various resistances similar to marketed inhaler products. For this measurement, the device was set to resistance equal to the product Turbuhaler S.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":null},{"groupId":"OG001","value":"3.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pre-dose PIF (Resistance Set Equal to ELLIPTA) Following 1 Week of Treatment","description":"Change from baseline in pre-dose PIF (resistance set equal to ELLIPTA) following 1 week of treatment was defined as the pre-dose PIF (resistance set equal to ELLIPTA) following 1 week of treatment minus baseline PIF. (The InCheck Inspiratory Flow Measurement Device is an inhalation airflow meter that may be set to various resistances similar to marketed inhaler products. For this measurement, the device was set to resistance equal to the product ELLIPTA.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null},{"groupId":"OG001","value":"2.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post-dose FEV1 Following the First Dose","description":"Change from baseline in 2-hour post-dose FEV1 following the 1st dose of treatment was defined as the 2-hour post-dose assessment of FEV1 following the 1st dose of treatment (Visit 3 or 5) minus baseline FEV1.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.136","spread":null},{"groupId":"OG001","value":"0.093","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post-dose IC Following the First Dose","description":"Change from baseline in 2-hour post-dose IC following the 1st dose of treatment was defined as the 2-hour post-dose assessment of IC following the 1st dose of treatment (Visit 3 or 5) minus baseline IC.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.264","spread":null},{"groupId":"OG001","value":"0.258","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":33},"commonTop":["Angina pectoris","Abdominal discomfort"]}}}